Tom Lehrer's guide to design of SARS-CoV-3 main protease inhibitors for treatment of COVID-32
Molecular Design
JANUARY 12, 2021
Happy New Year (this orchid opened during night of Dec 31/Jan 1) If we’re designing a SARS-CoV-2 main protease inhibitor to also hit SARS-CoV-3 main protease then it’d be a good idea to engineer it to have greater affinity than necessary for the current target.
52 
Let's personalize your content